Trevi Therapeutics Quarterly Cash Flow Statement
NASDAQ: TRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.19+0.365 (+2.85%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Trevi Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Trevi Therapeutics generated -$17.4 million of operating cash flow and spent $124,000 on capital expenditures. That left free cash flow of -$17.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Trevi Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -17.80M | -13.19M | -8.32M | -11.80M | -12.30M | -10.34M | -11.41M | -13.24M | -12.35M | -10.90M | -7.82M | -7.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 34.00K | 34.00K | 31.00K | 38.00K | 38.00K | 37.00K | 38.00K | 36.00K | 38.00K | 35.00K | 35.00K | 35.00K |
| Stock-Based Compensation | 3.27M | 2.19M | 1.35M | 1.24M | 1.38M | 1.21M | 917.00K | 822.00K | 1.13M | 723.00K | 534.00K | 530.00K |
| Change in Working Capital | -2.52M | -5.40M | -274.00K | -169.00K | 1.05M | -4.10M | 1.01M | 3.15M | 2.73M | -62.00K | 736.00K | 207.00K |
| Operating Cash Flow | -17.43M | -16.69M | -7.63M | -10.88M | -10.10M | -13.48M | -9.55M | -9.56M | -8.68M | -10.47M | -6.36M | -7.28M |
| Capital Expenditures | -124.00K | -102.00K | 0 | -12.00K | — | — | -7.00K | 0 | — | — | -22.00K | -18.00K |
| Investing Cash Flow | -112.04M | 16.96M | -30.61M | -50.94M | -2.61M | -9.95M | -23.87M | 7.67M | 2.77M | -8.09M | 12.85M | 17.98M |
| Debt Repaid | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Financing Cash Flow | 164.36M | 222.00K | 284.00K | 1.63M | 110.39M | 8.71M | 51.47M | 4.98M | 5.07M | -28.00K | -54.00K | 1.51M |
| Net Change in Cash | 34.89M | 498.00K | -37.95M | -60.19M | 97.68M | -14.72M | 18.05M | 3.09M | -848.00K | -18.59M | 6.43M | 12.21M |
| Free Cash Flow | -17.55M | -16.79M | -7.63M | -10.89M | -10.10M | -13.48M | -9.56M | -9.56M | -8.68M | -10.47M | -6.38M | -7.30M |
This table shows 12 quarterly periods of Trevi Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TRVI's reporting calendar. What is a cash flow statement?